- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03080597
PrEP for HBCUs (Study 2) (PrEP for HBCUs)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The following is only pertaining to study 2, HBCUs. PrEP Smart (study 1) is not included in this record.
The investigators' overall goals are to target (a) pre-exposure prophylaxis (PrEP) uptake by addressing access and acceptability and (b) PrEP adherence among Historically Black Colleges and Universities (HBCU) students.
Aim 1/Study 1. Investigate uptake of PrEP services on HBCU campuses. Making PrEP available on HBCU campuses may address uptake by increasing (a) accessibility by allowing students to gain access to tenofovir disproxil fumarate/emtricitabine (TDF/FTC) without having to leave campus and (b) acceptability by providing trained practitioners and student advocates on campus to educate students on the benefits of PrEP. Aim 1a will target PrEP uptake at HBCUs at the healthcare systems level. The investigators will identify Student health centers (SHC) practitioners on 6 HBCUs (North Carolina Central, St. Augustine's, Fayetteville State University, Shaw, North Carolina A&T, and Bennett College). After a comprehensive SHC needs assessment, the investigators will train practitioners on eligibility for PrEP, pre-initiation counseling, and prescribing in partnership with the North Carolina AIDS Education and Training Center (NC AETC). The investigators will also engage key student organizations on campus and train motivated student advocates for the dissemination of information about PrEP on campus. Aim 1b will target PrEP uptake at the individual level. First, the investigators will collect data on all clinical encounters for PrEP at participating SHCs during the study period. Data will be collected on the basic demographics and risk factors necessitating the initiation of PrEP. The investigators will also collect data on PrEP initiations, as well as the number of prescriptions written in follow up during the period of study. To better understand PrEP behaviors on campus, the investigators will ask students initiated on PrEP to take a brief, anonymous questionnaire on relevant topics including: (1) PrEP awareness, (2) Motivation for initiating PrEP, (3) Perceived stigma of HIV and HIV associated risk factors on campus, and (4) Perceptions of confidentiality regarding seeking PrEP services on campus. The investigators anticipate enrolling approximately 250 students for this portion of the study.
Aim 2/Study 2. Adapt a smartphone-based contingency management (CM) application ("app") intervention designed to improve PrEP adherence. CM is a behavioral intervention that involves the systematic use of reinforcement dependent on the occurrence of a predefined behavior. CM improves adherence to antiretroviral therapy (ART) and post-exposure prophylaxis (PEP), and is currently being developed by the investigative team for PrEP. Since the cost of traditional CM interventions may be prohibitive in practice, the investigators will adapt this intervention using a lower cost reinforcement procedure and therefore improve the scalability of this adherence intervention. In a sample of young men who have sex with men (YMSM) prescribed PrEP (n = 20) over an 8 week period, Aim 2a will assess app interaction to address feasibility, Aim 2b will assess acceptability via self-report quantitative ratings and qualitative interviewing, Aim 2c will assess the validity of daily camera-based medication ingestion assessment via the app to validate medication adherence against blood tests to detect PrEP, and Aim 2d will assess barriers to adherence via app-based daily assessments following missed doses.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Duke University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Enrolled as a student in a Historically Black College or University, OR identify as Black/African American
- Male
- Self-report having sex with men in the past 6 months
- 18-30 years of age
- English-speaking
- Currently prescribed PrEP (Truvada) for HIV prevention
- Participant has an Android (using v5.x.x or lollipop) or iOS (v6.0) smartphone
Exclusion Criteria:
- History of a chronic/significant medical or psychiatric condition that will interfere with study participation
- Unable to attend sessions
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Viabilidad del dispositivo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Smartphone app condition
English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called "PrEP Smart".
|
English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called "PrEP Smart".an
application on their smart phones called "PrEP Smart".
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Feasibility as measured by the number of times per day that subjects initiate an interaction with PrEP Smart
Periodo de tiempo: 8 weeks
|
As measured by the number of times per day that subjects initiate an interaction with PrEP Smart
|
8 weeks
|
Feasibility as measured by the number of times per day that subjects respond to a PrEP Smart prompt
Periodo de tiempo: 8 weeks
|
As measured by the number of times per day that subjects respond to a PrEP Smart prompt
|
8 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Acceptability will be assessed during the final laboratory visit with an open ended qualitative interview assessing overall feedback
Periodo de tiempo: 8 weeks
|
Will be assessed during the final laboratory visit with an open ended qualitative interview assessing overall feedback.
|
8 weeks
|
Acceptability will be assessed by feedback specific to each of the six individual PrEP Smart features
Periodo de tiempo: 8 weeks
|
Will be assessed by feedback specific to each of the six individual PrEP Smart features.
|
8 weeks
|
Adherence will be assessed by the number of times that PrEP was taken daily over the 8 week period and the number of times that it was taken outside of a one hour window in which it was prescribed
Periodo de tiempo: 8 weeks
|
Will be assessed by the number of times that PrEP was taken daily over the 8 week period and the number of times that it was taken outside of a one hour window in which it was prescribed.
|
8 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: John T Mitchell, Ph.D., Study Principal Investigator
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- Pro00076107
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre PrEP Smart app
-
University of MinnesotaAmerican Cancer Society, Inc.; Melanoma Research AllianceTerminadoMelanoma (piel)Estados Unidos
-
Northwestern UniversityAmerican Cancer Society, Inc.TerminadoCáncer de mamaEstados Unidos
-
Hilary L Surratt, PhDNational Institute on Drug Abuse (NIDA)Activo, no reclutandoPrevención del VIHEstados Unidos
-
Ministry of Science and Technology, TaiwanFu Jen Catholic UniversityReclutamientoCondiciones Infantiles | Amamantamiento | Ansiedad pospartoTaiwán
-
University of Illinois at Urbana-ChampaignTerminadoActividad físicaEstados Unidos
-
Hoffmann-La RocheRoche Diabetes Care Deutschland GmbHTerminado
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Kenyatta National...TerminadoInfecciones por VIH | Relacionado con el embarazoKenia
-
3-C Institute for Social DevelopmentUniversity of WashingtonReclutamientoServicios de salud mentalEstados Unidos
-
University College DublinIrish Research CouncilTerminadoBienestar y salud mental generalIrlanda
-
Montefiore Medical CenterNew York State Psychiatric InstituteActivo, no reclutando